A Phase II Study of Weekly Dose-Dense Nanoparticle Paclitaxel (ABI-007), Carboplatin With Herceptin (RM) As First-Line Therapy of Advanced HER-2 Positive Breast Cancer

Trial Profile

A Phase II Study of Weekly Dose-Dense Nanoparticle Paclitaxel (ABI-007), Carboplatin With Herceptin (RM) As First-Line Therapy of Advanced HER-2 Positive Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2013

At a glance

  • Drugs Paclitaxel (Primary) ; Carboplatin; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Abraxis BioScience; American BioScience
  • Most Recent Events

    • 06 Feb 2010 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
    • 06 Feb 2010 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
    • 02 Feb 2010 Actual patient number (32) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top